在针对1型糖尿病患者的1期临床试验中,SAB Biotherapeutics Inc研发的SAB-142展现出令人鼓舞的早期数据,显示出对C肽保留的积极信号。这一发现为开发潜在的新型疗法提供了重要科学依据。
在针对1型糖尿病患者的1期临床试验中,SAB Biotherapeutics Inc研发的SAB-142展现出令人鼓舞的早期数据,显示出对C肽保留的积极信号。这一发现为开发潜在的新型疗法提供了重要科学依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.